Diagnosis Co-Occurrence
Patients with multiple chronic diseases constitute a small minority of the total population but the majority of healthcare [...]
Patients with multiple chronic diseases constitute a small minority of the total population but the majority of healthcare [...]
To achieve savings benefits from the coming wave of biosimilars, biosimilars must be adopted by prescribers, members, [...]
Once the first Humira biosimilar, Amjevita, launched in the United States in January, payers needed to begin [...]
Introduction There is a coming wave of changes arriving soon to the pharmacy market in the form of [...]
Introduction I read the 725-page draft of the Deficit Reduction Act[1] so you don’t have to. Well, [...]